Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Why It Matters

The turnaround shows Sanuwave can grow revenue and achieve profitability despite CMS reimbursement pressures, positioning it for continued expansion in the wound‑care market.

Key Takeaways

• Q4 2025 revenue hit $13.4M, up 29.7% YoY.
• Full-year 2025 revenue reached $44.1M, 35% growth.
• Gross margin slipped to 74.7% in Q4 due to write‑off.
• Adjusted EBITDA rose to $13.6M, nearly double prior year.
• 2026 guidance targets $51‑55M revenue, 16‑25% growth.

Pulse Analysis

Sanuwave Health posted a historic quarter, with Q4 2025 revenue climbing to $13.4 million—a 29.7 percent jump from the same period a year earlier—and full‑year sales reaching $44.1 million, up 35 percent. The surge reflects accelerating adoption of its FDA‑cleared UltraMist® wound‑care system, which benefits from a growing emphasis on non‑invasive regenerative therapies. Despite a tightening CMS reimbursement environment for skin substitutes, the company leveraged its consumables business, which now accounts for roughly half of total revenue, to offset pricing pressure. These results underscore Sanuwave’s ability to capture market share in a fragmented wound‑care sector.

Profitability showed mixed signals; the quarter’s gross margin fell to 74.7 percent, down from 77.9 percent a year earlier, largely because of a $486 thousand inventory write‑off on the PACE line. Excluding that charge, margin would have approached 78 percent, indicating underlying pricing power. Operating income held steady at $2.0 million, while adjusted EBITDA surged to $13.6 million for the year, more than doubling 2024 levels. Net income turned positive thanks to a favorable change in the fair‑value of derivative liabilities, a non‑recurring boost that investors should monitor for sustainability.

Looking ahead, Sanuwave projects 2026 revenue between $51 million and $55 million, implying 16‑25 percent growth and a Q1 target of $9.6‑10.3 million. The outlook rests on expanding the UltraMist® platform and deepening consumables sales, while the company’s balance sheet now carries $25.3 million of senior secured debt and $5.6 million of current loan obligations. Cash and equivalents sit at roughly $12 million, providing liquidity for R&D and potential acquisitions. If the firm can sustain margin expansion and reduce reliance on one‑off derivative gains, it could solidify its position as a leading niche player in the evolving wound‑care market.